Literature DB >> 12612318

Present treatment options for atrial fibrillation.

S K S Lairikyengbam1, M H Anderson, A G Davies.   

Abstract

Atrial fibrillation is the commonest sustained cardiac arrhythmia. It accounts for >35% of all hospital admissions for cardiac arrhythmias in the United States. The presence of atrial fibrillation increases the mortality of a population by up to twofold. The risk of stroke increases from 1.5% in patients with atrial fibrillation from 50-59 years of age to up to 23.5% for such patients aged 80-89 years. Although the diagnosis of atrial fibrillation is usually straightforward, effective treatment is not. This article will discuss how rhythm control of atrial fibrillation can best be achieved, the controversy over the rhythm versus rate control, the maintenance of sinus rhythm with antiarrhythmic drugs after cardioversion, and prevention of thromboembolism. Finally, the recent advances in various non-pharmacological approaches for the treatment of atrial fibrillation will be highlighted.

Entities:  

Mesh:

Year:  2003        PMID: 12612318      PMCID: PMC1742614          DOI: 10.1136/pmj.79.928.67

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  41 in total

Review 1.  Nonpharmacological treatment of atrial fibrillation: a heretic's appraisal.

Authors:  P E Vardas
Journal:  Pacing Clin Electrophysiol       Date:  2000-03       Impact factor: 1.976

Review 2.  Therapy of atrial fibrillation: rhythm control versus rate control.

Authors:  J Carlsson; J Neuzner; Y D Rosenberg
Journal:  Pacing Clin Electrophysiol       Date:  2000-05       Impact factor: 1.976

3.  Implementation of antithrombotic management in atrial fibrillation.

Authors:  S K Lairikyengbam; A G Davies; P D Jones
Journal:  Postgrad Med J       Date:  2001-07       Impact factor: 2.401

4.  Role of conscious sedation for external cardioversion.

Authors:  R Raipancholia; L Sentinella; M Lynch
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

5.  Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation.

Authors:  S A Chen; M H Hsieh; C T Tai; C F Tsai; V S Prakash; W C Yu; T L Hsu; Y A Ding; M S Chang
Journal:  Circulation       Date:  1999-11-02       Impact factor: 29.690

6.  Changes in ultrastructural calcium distribution in goat atria during atrial fibrillation.

Authors:  J Ausma; G D Dispersyn; H Duimel; F Thoné; L Ver Donck; M A Allessie; M Borgers
Journal:  J Mol Cell Cardiol       Date:  2000-03       Impact factor: 5.000

Review 7.  Classification system of atrial fibrillation.

Authors:  S Lévy
Journal:  Curr Opin Cardiol       Date:  2000-01       Impact factor: 2.161

8.  Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion.

Authors:  A Roijer; J Eskilsson; B Olsson
Journal:  Eur Heart J       Date:  2000-05       Impact factor: 29.983

9.  Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks.

Authors:  S Mittal; S Ayati; K M Stein; D Schwartzman; D Cavlovich; P J Tchou; S M Markowitz; D J Slotwiner; M A Scheiner; B B Lerman
Journal:  Circulation       Date:  2000-03-21       Impact factor: 29.690

10.  ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology.

Authors:  V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G De Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki
Journal:  J Am Coll Cardiol       Date:  2001-10       Impact factor: 24.094

View more
  2 in total

Review 1.  Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician.

Authors:  Renato D Lopes; Jonathan P Piccini; Elaine M Hylek; Christopher B Granger; John H Alexander
Journal:  J Thromb Thrombolysis       Date:  2008-09-21       Impact factor: 2.300

Review 2.  Stroke prevention in diabetic and other high cardiovascular risk patients.

Authors:  Fadi El-Atat; Tanja Rundek; James R Sowers; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2005-06       Impact factor: 4.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.